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Abstract 
Background: Neovascular age-related macular degeneration often requires chronic therapy with anti-VEGF agents, 
and patients with recurrent disease are challenging to manage.
Methods: This retrospective case series evaluates patients who were switched from bevacizumab or ranibizumab 
to aflibercept and then back again because of recurrent fluid on optical coherence tomography (OCT) by reporting 
changes in OCT measurements over the course of medication changes.
Results: Twenty-one eyes in nineteen patients received an average of 20.7 bevacizumab and/or ranibizumab injec-
tions and then an average of 7.2 aflibercept injections before being switched back to bevacizumab or ranibizumab 
because of recurrent fluid on OCT. Median central macular thickness improved on transition from bevacizumab or 
ranibizumab (317 μm) to aflibercept (285 μm; p = 0.034), then worsened over the course of aflibercept treatment 
(296 μm; p = 0.080), but improved again with transition from aflibercept back to bevacizumab or ranibizumab 
(283 μm; p = 0.016). The total volume of subretinal fluid, intraretinal fluid, and pigment epithelial detachments also 
decreased on transition from bevacizumab or ranibizumab (2.56 mm3) to aflibercept (2.44 mm3; p = 0.080), then 
worsened over the course of aflibercept treatment (3.18 mm3; p = 0.019), and improved again on transition back to 
bevacizumab or ranibizumab (2.11 mm3; p = 0.016).
Conclusions: While aflibercept appears initially effective, some patients develop recurrent fluid with aflibercept that 
improves with transition back to bevacizumab or ranibizumab. Rotating anti-VEGF agents may be beneficial with 
recurrent neovascular activity.
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Background
Intravitreal anti-vascular endothelial growth factor 
(VEGF) medications bevacizumab and ranibizumab are 
recognized for improving visual outcomes and decreas-
ing macular fluid in patients with neovascular age-
related macular degeneration (AMD) [1, 2]. Over time, 
decreased responsiveness to these medications has been 
described in some patients [3–5]. Since late 2011, afliber-
cept has been shown to have similar improvements in 
visual outcomes and macular fluid as bevacizumab or 
ranibizumab [6]. Patients demonstrating recurrent or 
persistent fluid on bevacizumab or ranibizumab have 
been transitioned to aflibercept, with many patients 
responding favorably [7]. However, a select number of 
patients have worsened with persistent or recurrent fluid 
on aflibercept [8–10]. Having demonstrated persistent 
or recurrent fluid on bevacizumab or ranibizumab and 
aflibercept, these patients are a challenge to treat. We 
report a series of patients who initially responded well to 
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aflibercept after having been treated with ranibizumab or 
bevacizumab but subsequently developed recurrences of 
fluid, and then were switched back to either ranibizumab 
or bevacizumab.
Methods
Institutional review board approval was granted by the 
University of California, San Francisco (UCSF), and all 
research was compliant with the Health Insurance Port-
ability and Accountability Act. This exploratory, ret-
rospective case series examined UCSF and Northern 
California Retina Vitreous Associates (NCRVA) patients 
with neovascular AMD between January 1, 2012 and 
March 14, 2014 who had been initially treated with mul-
tiple injections of 0.5 mg ranibizumab or 1.25 mg beva-
cizumab, then switched to 2 mg injections of aflibercept 
due to persistent or recurrent fluid on optical coher-
ence tomography (OCT), and subsequently switched 
back to 0.5  mg ranibizumab or 1.25  mg bevacizumab, 
again, due to recurrent or persistent fluid on OCT. Cri-
teria for medication switch to aflibercept and then back 
to ranibizumab/bevacizumab were the same: the pres-
ence of persistent or recurrent macular fluid, namely 
intraretinal fluid or subretinal fluid. Treatment schedules 
were dependent on the discretion of the treating reti-
nal specialist and patient availability. Patients were only 
included if they had received at least three injections of 
bevacizumab or ranibizumab prior to aflibercept, fol-
lowed by at least three injections of aflibercept, in order 
to better evaluate response to these medications.
Outcome variables included best available visual acuity 
(VA) converted to logMAR (logarithm of minimum angle 
of resolution), central macular thickness (CMT) [9, 11], 
and estimated volumes of pigment epithelium detachments 
(PED), subretinal fluid (SRF), and intraretinal fluid (IRF) 
features when present on OCT (centered on the fovea) 
before and after medication changes from ranibizumab or 
bevacizumab to aflibercept and then from aflibercept to 
bevacizumab or ranibizumab. OCT 1 represents the last 
OCT taken while the patient was receiving ranibizumab 
or bevacizumab prior to aflibercept. OCT 2 represents the 
first OCT taken after being switched to aflibercept. OCT at 
time point 3 is the last OCT taken while the patient was on 
aflibercept, prior to being switched back to ranibizumab or 
bevacizumab. Finally, OCT at time point 4 represents the 
first OCT taken while the patient was retreated with ranibi-
zumab or bevacizumab. VA was collected during the same 
visits as OCT images. OCT images were acquired with the 
Heidelberg Spectralis (Heidelberg Engineering, Carlsbad, 
California) at UCSF and the Cirrus (Carl Zeiss Meditec, 
Dublin, California) at NCRVA. Machines had tracking soft-
ware to ensure that the same area in each eye was scanned 
on repeat visits. With Spectralis volume scans, the 19 
B-scans were 240  μm apart; whereas with Cirrus volume 
scans, the 128 B-scans were 47 μm apart.
Since OCT-calculated segmentation lines demonstrate 
a degree of error, especially in cases of severe AMD [12], 
all measurements were obtained manually using the cali-
per tool. CMT was obtained by measuring the distance 
between the foveal depression (or expected foveal depres-
sion in severe cases of IRF) and Bruch’s membrane. Esti-
mated volumes of macular fluid on OCT were calculated 
by adapting simplified volumetric grading [13]. The max-
imum width and height of a feature were measured and 
the number of B-scans on which the feature appeared 
were counted. These calculations were then multiplied 
by distance between B-scans, yielding an estimated volu-
metric cube encapsulating the feature.
Demographic data included patient age and sex, num-
ber of ranibizumab, bevacizumab, and aflibercept injec-
tions, and timing of each of those injections.
VA and OCT measurements were not normally dis-
tributed and are presented as medians with interquartile 
ranges. Changes in these variables over time (between 
sequential OCTs: OCT 1, OCT 2, OCT 3, OCT 4) were 
analyzed using Wilcoxon signed-rank tests. Friedman’s 
tests were performed for each of the variables (CMT, 
SRF, IRF, PED, Total Volume, VA) to assess for differences 
over the course of medication changes. Patients were also 
divided by treatment group: patients who had received 
ranibizumab, then aflibercept, and then ranibizumab 
again; patients who had received bevacizumab, then 
aflibercept, and then bevacizumab again; and patients 
who had received all three medications over the course 
of their treatment. Medians and interquartile ranges of 
OCT measurements were evaluated for each treatment 
group. Given the nature of our non-parametric data, we 
did not feel ANOVA was appropriate to evaluate dif-
ferences between treatment groups. Instead, Wilcoxon 
signed-rank tests were again used to evaluate changes 
between sequential OCTs, and Friedman’s tests were 
performed for each of the OCT variables by treatment 
group. Statistical analyses were performed using Stata 14 
(StataCorp, College Station, Texas).
Results
At UCSF, 80 eyes with neovascular AMD were transi-
tioned from bevacizumab or ranibizumab to afliber-
cept. Of these, 25 eyes (31 %) were transitioned back to 
ranibizumab after at least one aflibercept injection; 9 eyes 
(11.3  %) were transitioned off aflibercept after at least 
three injections. Patients were transitioned from afliber-
cept to ranibizumab after a single injection because of 
immediate worsening on OCT or patient preference 
given immediate worsening of VA. We identified 21 eyes 
in 19 patients at UCSF and NCRVA who met inclusion 
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criteria (Table 1) and had received at least three ranibi-
zumab or bevacizumab injections prior to aflibercept and 
then at least three aflibercept injections. These 21 eyes 
had received an average of 20.7 ranibizumab and/or bev-
acizumab injections (10 eyes had only received ranibi-
zumab, 4 eyes had only received bevacizumab, and 7 eyes 
had had both), followed by an average of 7.2 aflibercept 
injections before being switched back to ranibizumab or 
bevacizumab (with 14 eyes transitioning to ranibizumab 
and 7 eyes transitioning to bevacizumab) by retinal spe-
cialists because of persistent or recurrent fluid on OCT. 
Patients received aflibercept injections every 6  weeks 
on average, and were then treated with ranibizumab or 
bevacizumab about 6  weeks after their last aflibercept 
injection. Thus, in this group of patients, aflibercept 
represented 2nd-line treatment in 14 eyes, and 3rd-line 
treatment in 7 eyes that had received sequential peri-
ods of ranibizumab as well as bevacizumab prior to 
aflibercept.
Median CMT improved from 317  µm (interquar-
tile range (IQR), 259.5–362.5  μm) on ranibizumab or 
bevacizumab at OCT time point 1 to 285  µm (IQR, 
228–337  μm) on aflibercept at OCT time point 2 
(p =  0.034) (Table  2), then worsened to 296  µm (IQR, 
231.5–409 μm; p = 0.080) at OCT time point 3 during 
aflibercept treatment, and improved again to 283  µm 
(IQR, 229.5–374.5  µm; p  =  0.016) at OCT time point 
4 when switched back to ranibizumab or bevacizumab. 
Of note, CMT on returning back to ranibizumab or 
bevacizumab (283 µm) was significantly improved from 
prior measurement while on ranibizumab or bevaci-
zumab before aflibercept (317  µm; p =  0.029). A simi-
lar trend in macular fluid was noted over the course of 
medication changes. The total volume of SRF, IRF, and 
PED decreased from 2.56  mm3 (IQR, 1.05–4.47  mm3) 
on ranibizumab or bevacizumab to 2.44 mm3 on afliber-
cept (IQR, 1.03–4.54  mm3; p =  0.080), then increased 
during aflibercept treatment (3.18  mm3; IQR, 0.96–
4.39 mm3; p = 0.019), and decreased again upon switch-
ing back to ranibizumab or bevacizumab (2.11  mm3; 
IQR, 0.82–3.57 mm3; p = 0.016). Median values for SRF, 
Table 1 Patient characteristics
Description of patients with chronic neovascular age-related macular 
degeneration transitioned from bevacizumab or ranibizumab to aflibercept and 
then back to bevacizumab or ranibizumab
Total eyes, N 21
Total patients, N 19
Female, N (%) 11 (58)
Age, years (range) 79 (67–95)
Number of bevacizumab and ranibizumab injections prior 
to aflibercept, mean (range)
20.71 (3–49)
Aflibercept injections, mean (range) 7.19 (3–14)
Injection interval in weeks while on aflibercept, mean ± SD 6.08 ± 1.12
Injection interval in weeks between last aflibercept injec-
tion and first bevacizumab or ranibizumab injection, 
mean ± SD
5.97 ± 3.24
Table 2 Optical coherence tomography measurements 
and visual acuity over the course of medication changes
Treatment response of patients with chronic neovascular age-related macular 
degeneration switched from bevacizumab or ranibizumab to aflibercept and 
then back to bevacizumab or ranibizumab
OCT 1 represents the last OCT on bevacizumab or ranibizumab prior to 
transition to aflibercept. OCT 2 represents the first OCT after switching to 
aflibercept. OCT 3 indicates the last OCT on aflibercept before transition back 
to bevacizumab or ranibizumab. OCT 4 represents the first OCT after switching 
back to bevacizumab or ranibizumab
a Comparing response from bevacizumab or ranibizumab (OCT 1) to aflibercept 
(OCT 2)
b Comparing progression while on aflibercept (OCT 2 and OCT 3)
c Comparing response back to bevacizumab or ranibizumab (OCT 4) from 
aflibercept (OCT 3)
d Summation of subretinal fluid, intraretinal fluid, and pigment epithelial 
detachments







Central macular thickness (CMT), μm <0.001
 OCT 1 317 (259.5–362.5)
 OCT 2 285 (228–337) 0.034a
 OCT 3 296 (231.5–409) 0.080b
 OCT 4 283 (229.5–374.5) 0.016c
Total fluid volumed, mm3 <0.001
 OCT 1 2.56 (1.05–4.47)
 OCT 2 2.44 (1.03–4.54) 0.080a
 OCT 3 3.18 (0.96–4.39) 0.019b
 OCT 4 2.11 (0.82–3.57) 0.016c
Subretinal fluid (SRF), mm3 <0.001
 OCT 1 0.16 (0.01–0.88)
 OCT 2 0.19 (0.006–0.59) 0.018a
 OCT 3 0.34 (0.04–1.42) 0.057b
 OCT 4 0.11 (0–0.36) 0.003c
Intraretinal fluid (IRF), mm3 <0.001
 OCT 1 0.007 (0–0.44)
 OCT 2 0.002 (0–0.11) 0.102a
 OCT 3 0.12 (0–0.78) 0.019b
 OCT 4 0.0005 (0–0.44) 0.336c
Pigment epithelial detachment (PED), mm3 <0.001
 OCT 1 2.00 (0.64–3.27)
 OCT 2 1.64 (0.71–3.40) 0.307a
 OCT 3 1.95 (0.65–2.79) 0.238b
 OCT 4 1.76 (0.53–2.55) 0.179c
Visual acuity (VA), logMARe <0.001
 OCT 1 0.30 (0.18–0.48)
 OCT 2 0.30 (0.18–0.44) 0.175a
 OCT 3 0.30 (0.14–0.57) 0.292b
 OCT 4 0.30 (0.18–0.60) 0.104c
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IRF, and PED showed a tendency to improve with the 
transition from ranibizumab or bevacizumab to afliber-
cept, then worsen over the course of aflibercept treat-
ment, and improve again on transition from aflibercept 
back to ranibizumab or bevacizumab, but not all of 
these changes proved to be statistically significant on 
Wilcoxon signed-rank tests. In the majority of eyes, 
SRF improved significantly (p  =  0.018) on transition 
to aflibercept from ranibizumab or bevaciumab even 
though the median showed a small increase from 0.16 
to 0.19 mm3. SRF (p = 0.057) and IRF (p = 0.019) wors-
ened during the course of aflibercept treatment, and 
SRF (p  =  0.003) showed significant improvement on 
transition back to ranibizumab or bevacizumab from 
aflibercept. SRF on transition back to ranibizumab or 
bevacizumab was also significantly improved from prior 
measurement on ranibizumab or bevacizumab before 
aflibercept (p =  0.036) (Fig.  1). All other changes over 
time were non-significant. Percent change in OCT 
measurements between sequential OCT time points 
was <25  % for all measurements, except for a median 
35  % decrease in SRF from OCT 1 to OCT 2, a 37  % 
decrease in SRF from OCT 3 to OCT 4, and a 26  % 
decrease in Total Volume from OCT 3 to OCT 4. Fried-
man’s tests for all variables (CMT, SRF, IRF, PED, total 
volume) were statistically significant (p  <  0.001) and 
confirm differences in macular features over the course 
of multiple medication changes.
Only two patients received bevacizumab, then afliber-
cept, followed by a return to bevacizumab. Ten patients 
received ranibizumab followed by aflibercept before 
being transitioned back to ranibizumab. Nine patients 
received all three medications over the course of their 
treatment. Medians and interquartile ranges (IQR) of 
OCT measurements are presented for the latter two 
treatment groups (Table  3). Overall, patients who had 
received all three medications over the course of their 
treatment demonstrated less macular volume than 
patients in the ranibizumab-aflibercept-ranibizumab 
group. All Friedman’s tests for CMT, total volume, SRF, 
IRF, and PED by treatment group were statistically 
significant.
Median VA showed little apparent change with transi-
tion from ranibizumab or bevacizumab (logMAR 0.30; 
IQR, 0.18–0.48) to aflibercept (logMAR 0.30; IQR, 0.18–
0.44; p = 0.175), over the course of aflibercept treatment 
(0.30; IQR, 0.14–0.57; p  =  0.292), or transition back 
to ranibizumab or bevacizumab (0.30; IQR, 0.18–0.60; 
p  =  0.104). Friedman’s test was statistically significant 
over the course of medication changes.

































































































































Fig. 1 Optical coherence tomography (OCT) changes over the course of medication changes. Median values and interquartile ranges of central 
macular thickness, total fluid volume, subretinal fluid, intraretinal fluid, and pigment epithelial detachments over the course of anti-VEGF medica-
tion changes from OCT 1 (while patients were on bevacizumab or ranibizumab prior to aflibercept treatment) to OCT 2 (shortly after transitioning 
to aflibercept treatment), then OCT 3 (while patients were on aflibercept treatment prior to transition back to bevacizumab or ranibizumab), and 
finally OCT 4 (shortly after patients were re-started on bevacizumab or ranibizumab)
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Discussion
Our retrospective study included patients with recur-
rent or increasing persistent fluid on OCT while on 
ranibizumab or bevacizumab who had been switched to 
aflibercept and then switched back to ranibizumab or 
bevacizumab because of persistent or recurrent fluid on 
OCT while on aflibercept. OCT measurements exhibited 
a unifying trend: CMT and macular fluid volume showed 
some improvement with initial transition from ranibi-
zumab or bevacizumab to aflibercept, but these improve-
ments dissipated over the course of aflibercept treatment. 
After switching back to bevacizumab or ranibizumab, 
CMT and macular volume once again showed some ini-
tial improvements. Moreover, CMT and SRF on transi-
tion from aflibercept to bevacizumab or ranibizumab 
were improved even beyond last measurement on beva-
cizumab or ranibizumab prior to starting aflibercept.
Evaluation of response to anti-VEGF medication is 
often reserved for at least 1  month after completion 
of loading doses (or 3 monthly doses) [14], but many 
patients show immediate worsening on aflibercept, likely 
due to innate resistance. The patients in this study were 
Table 3 Changes in optical coherence tomography measurements by treatment group
Treatment response of chronic neovascular age-related macular degeneration patients by treatment group: ranibizumab-aflibercept-ranibizumab vs. ranibizumab/
bevacizumab-aflibercept-ranibizumab/bevacizumab
Patients were divided into three treatment groups: those patients who had received bevacizumab only, then aflibercept, and then bevacizumab again (bevacizumab-
aflibercept-bevacizumab), those patients who had received ranibizumab only, then aflibercept, and then ranibizumab again (ranibizumab-aflibercept-ranibizumab), 
and those patients who had received all three medications over the course of their treatment (ranibizumab/bevacizumab-aflibercept-ranibizumab/bevacizumab). The 
bevacizumab-aflibercept-bevacizumab group contained only two patients and was thus excluded from further analysis
a Comparing response from bevacizumab or ranibizumab (OCT 1) to aflibercept (OCT 2)
b Comparing progression while on aflibercept (OCT 2 and OCT 3)
c Comparing response back to bevacizumab or ranibizumab (OCT 4) from aflibercept (OCT 3)
















Median (interquartile range) Median (interquartile range)
Central macular thickness (CMT), μm 0.002 0.001
 OCT 1 335.5 (308.25–381.75) 283 (252.5–382.5)
 OCT 2 302.5 (222–360.75) 0.030a 285 (220.5–442.5) 0.38a
 OCT 3 375 (292.75–435.25) 0.016b 295 (216.5–392.5) 0.22b
 OCT 4 314 (232.5–399.75) 0.021c 248 (212.5–333.5) 0.037c
Total Fluid Volumed, mm3 0.007 0.003
 OCT 1 3.50 (2.47–5.52) 1.68 (0.71–5.28)
 OCT 2 3.55 (1.49–4.73) 0.121a 1.36 (0.58–4.20) 0.221a
 OCT 3 4.28 (2.94–6.27) 0.018b 0.96 (0.76–3.85) 0.297b
 OCT 4 2.87 (2.31–4.31) 0.024c 0.77 (0.47–2.72) 0.087c
Subretinal fluid (SRF), mm3 0.007 0.003
 OCT 1 0.11 (0.013–1.12) 0.16 (0.003–0.82)
 OCT 2 0.15 (0–0.76) 0.091a 0.11 (0.006–0.59) 0.077a
 OCT 3 0.68 (0.01–1.68) 0.178b 0.33 (0.04–1.15) 0.077b
 OCT 4 0.06 (0–0.40) 0.004c 0.09 (0.008–0.31) 0.038c
Intraretinal fluid (IRF), mm3 0.003 0.010
 OCT 1 0.04 (0–1.74) 0 (0–0.73)
 OCT 2 0.008 (0–0.07) 0.032a 0.0002 (0–0.49) 0.426a
 OCT 3 0.22 (0.0006–0.96) 0.012b 0 (0–0.59) 0.335b
 OCT 4 0.0009 (0–0.99) 0.206c 0 (0–0.44) 0.377c
Pigment Epithelial Detachment (PED), mm3 0.0003 0.003
 OCT 1 2.39 (1.77–3.23) 0.67 (0.18–3.85)
 OCT 2 2.36 (1.35–4.38) 0.222a 0.83 (0.20–3.40) 0.430a
 OCT 3 2.49 (1.90–4.13) 0.070b 0.86 (0.18–2.63) 0.107b
 OCT 4 2.39 (2.05–3.23) 0.480c 0.50 (0.16–2.03) 0.187c
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given at least three aflibercept injections, then monitored 
for response, and found to have worsening persistent or 
recurrent fluid. Poor or worsening response could rep-
resent decreased treatment effectiveness or insufficient 
dosing. Since the majority of these patients demonstrated 
a modest initial improvement on OCT (albeit not >25 % 
improvement in many measurements) in response to 
medication changes, one could argue that this decreased 
effectiveness constitutes poor response or tachyphylaxis, 
rather than innate resistance which is characterized by 
worsening response from the first injection [11]. Tachy-
phylaxis, a clinical phenomenon referring to a progres-
sive decrease in therapeutic response after repetitive 
administration of a pharmacological active substance, 
has been well documented with numerous medications, 
including ranibizumab and bevacizumab [3–5]. While 
the longer dosing intervals in our case series do not 
allow us to evaluate for a possible role of tachyphylaxis, 
patients on consistent 4-week aflibercept dosing intervals 
who experience recurrent fluid on OCT may be suffering 
from a waning effect of aflibercept, or tachyphylaxis.
Improvement with transition to aflibercept may be 
explained by the medication’s increased binding affin-
ity for vascular endothelial growth factor-A (VEGF-A), 
VEGF-B, and placental growth factor [11]. Multiple 
reports have demonstrated that patients with ranibi-
zumab or bevacizumab tachyphylaxis respond positively 
to aflibercept [15]. Improvement with transition back 
to ranibizumab or bevacizumab is harder to explain 
but may be due to the different molecular structure of 
the medications. Ehlken et  al. have shown that nonre-
sponders to bevacizumab had VA improvements when 
switched to ranibizumab, or vice versa [16]. Gasperini 
et  al. demonstrated reductions in macular fluid in 81  % 
of patients with choroidal neovascularization who had 
developed tachyphylaxis on ranibizumab or bevacizumab 
and were switched to the other anti-VEGF medication 
[32]. These studies suggest that patients may respond dif-
ferently to all three anti-VEGF drugs. The mechanism of 
poor response is unclear but may be cellular, metabolic, 
and/or genetic. Poor response may involve compensatory 
signaling that leads to upregulation of pro-angiogenic 
factors and/or downregulation of anti-angiogenic factors, 
neutralizing antibodies, and/or genetic predisposition 
[14]. Moreover, many of the patients in this study have 
had AMD for many years and may also be suffering from 
changes in vessel wall structure or fibrosis that limit the 
effect of these medications [17].
Management of patients who demonstrate a poor 
response or non-response to multiple anti-VEGF agents 
is proving difficult. One suggested treatment option 
includes periodic transition between the various anti-
VEGF agents [3, 11, 18]. In our study, CMT and macular 
fluid had somewhat positive, albeit temporary, responses 
to anti-VEGF medication switches. In particular, CMT 
and SRF responded to ranibizumab or bevacizumab even 
after these eyes had been previously deemed non-respon-
sive to these medications, suggesting that drug rotation 
may help stabilize fluid accumulation. Medication vaca-
tion periods may be helpful [19]. Czarnowicki et al. [20] 
show that psoriasis plaques re-exposed to halobetasol 
ointment after a vacation period demonstrate greater 
improvement than plaques not previously exposed to 
halobetasol. Switching between different medications in 
the same class allows for an individual medication vaca-
tion period while at the same time continuing to treat a 
condition. Yang et  al. [21] describe switching back and 
forth between intrathecal bupivacaine and lidocaine to 
achieve pain relief. In our study, initial improvements 
in CMT and macular fluid volume were immediately 
apparent after starting aflibercept and after re-starting 
ranibizumab or bevacizumab. Other studies have shown 
decreases in CMT and macular fluid on aflibercept for 
chronic AMD patients with persistent or recurrent fluid, 
even after one injection [10, 22]. Thus, periodic transition 
between the various anti-VEGF agents may be an effec-
tive treatment option.
The question arises as to when to transition between 
the various anti-VEGF agents. In their comprehen-
sive literature review, Lazzeri et  al. suggest that CMT 
decrease by <100  µm or lack of total fluid reabsorption 
after 3–6 injections of a single anti-VEGF agent (namely 
ranibizumab or bevacizumab) should call into ques-
tion the drug’s effectiveness and warrant consideration 
of transition to aflibercept or another treatment option 
[11]. Amoaku et al. define a poor response to anti-VEGF 
treatment as <25 % decrease in central retinal thickness 
(CRT) and/or new or persistent IRF or SRF with minimal 
improvement in VA (0 to −4 ETDRS letters). They define 
non-response as unchanging CRT, SRF, IRF and/or PED 
with a worsening in VA (> −5 ETDRS letters) [14]. We 
feel that poor response or non-response to 3–6 monthly 
aflibercept injections warrants transition to another anti-
VEGF agent or a change in therapeutic strategy.
Shorter treatment intervals may also prove beneficial in 
managing these patients. Biweekly dosing of ranibizumab 
or bevacizumab has proven beneficial in poorly respon-
sive patients [23]. Future studies are needed to evaluate 
the usefulness of aflibercept injections given <28  days. 
Administration of aflibercept every 8 weeks may be too 
long for some patients, especially those with persistent 
fluid [24, 25]. The significant increase in total macular 
volume over the course of multiple aflibercept injections 
(mean 7; range 3–14) in our study may indicate the need 
for shorter time intervals between injections and/or an 
increasing non-responsiveness to aflibercept over time. 
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Unfortunately, monthly (or even more frequent) dosing 
of anti-VEGF medications is not always achievable in 
the real world, but should be considered in these difficult 
to manage patients. Additional treatment possibilities 
include increased drug dosages [18, 26, 27] and com-
bined treatment with other medications [3, 14]. Schaal 
et  al. [28] report improved outcomes when combining 
triamcinolone acetate with bevacizumab. Patients dem-
onstrating increasing non-responsiveness should also be 
evaluated for additional lesions or diagnoses with consid-
eration of photodynamic therapy for polypoidal choroi-
dal vasculopathy [29].
Prior evaluations of response to anti-VEGF medica-
tions on OCT have focused mostly on qualitative analy-
ses, retinal thickness estimates [8, 22], or PED height [7, 
11]. However, volumetric quantitative measurements 
provide greater insight into the response of SRF, IRF, and 
PED. Similar to other qualitative studies [3, 8, 21, 30], 
PEDs in our study showed comparatively less change in 
response to anti-VEGF medications as compared to other 
features on OCT. Also consistent with findings in other 
studies, VA did not change over the course of medication 
changes in these patients with chronic AMD [7, 9–11, 
22], suggesting that irreversible damage has occurred 
to retinal structures [31] or other factors such as outer 
retinal morphology (external limiting membrane integ-
rity, outer retinal layer thickness) [32–34] may play more 
important roles in VA than central macular fluid accu-
mulations or central macular thickness.
Limitations of this study include small sample size, 
retrospective nature, lack of standardized VA measure-
ments, several treating physicians acting without a stand-
ard treatment protocol, and short follow-up after return 
to ranibizumab or bevacizumab.
Conclusions
In conclusion, recurrence of neovascular activity can 
occur in patients with AMD on aflibercept therapy. 
Although these patients showed moderate initial CMT 
and macular fluid improvement on aflibercept, improve-
ments waned over the course of multiple aflibercept 
treatments, suggesting a need for shorter time intervals 
between injections. On transition back to ranibizumab 
or bevacizumab, patients again demonstrated initial 
improvement in CMT and macular fluid, sometimes even 
beyond last recorded measurements on ranibizumab or 
bevacizumab (prior to starting aflibercept). Since these 
patients showed some initial improvement on the differ-
ent anti-VEGF medications, they may benefit from peri-
odic rotation between the various anti-VEGF agents.
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